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Abstract
The gap between treatment development and efficacy testing to scaled up implementations of 
evidence base treatment (EBT) is an estimated 20 years, and hybrid research designs aim to reduce 
the gap. One was used for a multisite study in cancer control, testing co-primary aims: 1) 
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determine the feasibility and utility of a flexible EBT implementation strategy, and 2) determine 
the clinical effectiveness of an EBT as implemented by newly trained providers. Therapists from 
15 diverse sites implemented the biobehavioral intervention (BBI) for cancer patients (N=158) as 
part of standard care. For implementation, therapists determined treatment format, number of 
sessions, etc. and reported session-by-session fidelity. Patients completed fidelity and outcome 
assessments. Results showed therapists BBI implementation was done with fidelity, e.g., session 
“dose” (59%), core content coverage (60–70%), and others. Patient reported fidelity was favorable 
and comparable to the BBI efficacy trial. Effectiveness data show the primary outcome, patients’ 
scores on the Profile of Mood States total mood disturbance, significantly improved (R2=0.06, β=
−0.24, p < 0.01) as did a secondary outcome, physical activity (R2=0.02, β=0.13, p < 0.05). This 
first use of a hybrid design in health psychology provided support for a novel strategy that allowed 
providers implementation flexibility. Still, the EBT was delivered with fidelity and in addition, 
therapists generated novel procedures to enhance setting-specific usage of BBI and its ultimate 
effectiveness with patients. This research is an example of translational research spanning theory 
and efficacy tests to dissemination and implementation.
Keywords
Hybrid design; evidence based treatment; clinical effectiveness; implementation
Introduction
In an Institute of Medicine report, Crossing the quality chasm: A new health system for the 
21st century (Institute of Medicine, 2001), the lag time in translation between research to 
health care practice implementation was estimated to be 20 years, due to the failure to move 
treatment development and testing to scaled up implementations. Bridging the chasm is 
challenging as an analysis of contributory factors suggests. A key one is separateness of two 
research traditions. In clinical research, progress is linear, from efficacy to effectiveness 
studies, with the latter focus on generalizability of the treatment to other patient groups, 
locales of treatment delivery being in “the real world,” and evidence that the treatment, even 
with these transitions, can still achieve clinical (patient) and other (quality of life, cost 
reduction) outcomes. Quite apart is the domain of implementation, which assumes treatment 
effectiveness and focuses instead on treatment delivery, i.e., its fidelity and the generality of 
adoption among providers or in systems of care, including the discovery of facilitating and 
inhibiting factors at each level. “Pure forms” of each differ in the role of randomization, the 
unit of analysis, the nature of the intervention, and the measured outcomes. The respective 
contributions are relevant to the other but are mainly nonoverlapping, and notions of 
adjusting clinical research aims/designs to those of implementation (or vice versa) has been 
likened to “adapting square pegs to fit in round holes” (Onken, Carroll, Shoham, Cuthbert, 
& Riddle, 2014, p. 25). However, one pathway across the chasm may be a blending of each 
research tradition, thereby achieving more effective implementations and more rapid 
translation.
An effectiveness-implementation hybrid design as described by Curran, Bauer, Mittman, 
Pyne, and Setler (2012) is one with, a priori, a dual focus. Three types have been described, 
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with the type 1 hybrid testing effects of a clinical intervention on patient outcomes while 
observing and gathering information on implementation and type 3 testing an 
implementation strategy in terms of reach, acceptance, implementation, and sustainability 
(Glasgow, Vogt, & Boles, 1999), for example, while secondarily gathering information on 
the intervention’s patient outcomes. That used here, type 2, is a dual testing of a clinical 
intervention and an implementation strategy to support rapid translation. For a clinical 
intervention test, at least 1 outcome is measured and at least 1 hypothesis is examined. 
Regarding the implementation test, it assesses adoption of the clinical treatment and the 
fidelity of doing so. The test is conducted under a pragmatic set of conditions (rather than 
under “best” or “worse” case scenarios) to provide more valid estimates of clinical 
effectiveness.
Translational Discovery Leading to the Hybrid Design
Science leading to the described study is depicted in Fig. 1. This figure considers models of 
Khoury et al. (2010) and Onken et al. (2014). Boxes represent empirical efforts and 
pathways represent theory.
Box A: Scientific discovery (Andersen, Goyal, Westbrook, Bishop, & Carson, 2017). 
Studies conducted worldwide have documented the stress and quality of life disruption of 
cancer. Our work has highlighted an often-unrecognized aspect, i.e., cancer stress promotes 
a cascade of negative sequelae – some biologic, others behavioral – which, in turn, have 
their own negative consequences and impact the “whole cancer patient”
Path T1: Biobehavioral model of cancer stress and disease course (Andersen, Kiecolt-Glaser, 
& Glaser, 1994). A theory (see Fig. 2) conceptualized cancer stress and the accompanying 
biobehavioral responses leading to their hypothesized relationship to disease progression. 
Briefly, stress and depressive symptoms peak at diagnosis, they are accompanied by biologic 
changes (Andersen et al., 1998), and, if continued, quality of life declines (Golden-Kreutz et 
al., 2005). Negative health behaviors (e.g., alcohol use, smoking) may increase with stress 
(e.g., Armeli, Todd, & Mohr, 2005) and intensify its physiologic effects (e.g., Díaz et al., 
2002). Stress is a correlate of poor treatment compliance (e.g., Arrieta et al., 2013); patients 
becoming clinically depressed are more likely to discontinue treatment or die from it (e.g., 
Loberiza et al., 2002). Central nervous system (CNS) and neuroendocrine pathways leading 
to immunity are hypothesized. Stress and negative affect can contribute to dysregulation of 
the hypothalamic-pituitary-adrenal (HPA) axis (Thornton, Andersen, & Blakely, 2010) and 
decreased cellular immunity (Thornton, Andersen, Crespin, & Carson, 2007). Innate 
immune processes play a role in both cancer and depression and are thus also included. 
Systemic inflammation occurs when cancer cells are identified as foreign and/or when the 
tumor itself releases proinflammatory cytokines (Coussens & Werb, 2002). Even after the 
tumor is removed, inflammation can be triggered by adjuvant treatments, and inflammation 
predicts increased risk of recurrence and cancer death (Molica et al., 2002; Shankar et al., 
2006). Regarding depression, several studies have demonstrated that depressed cancer 
patients show innate immune activation (e.g., Irwin & Miller, 2007). Considering a negative 
feedback loop (depression←inflammation), proinflammatory cytokines, including TNF-
alpha, IL-1, and IL-6, interact with CNS pathways to regulate behavior. The latter pathways 
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may generate “sickness behaviors”(Dantzer, 2009), with neurovegetative signs and affective 
symptoms (fatigue, pain, sleep problems, cognitive impairment, depression).
Box B1: Test of the biobehavioral model and development of the intervention (Andersen et 
al., 2004, 2007, 2008, 2010). A RCT was designed to answer the following: “Would receipt 
of a psychological intervention designed to reduce stress and improve behavioral responses 
reduce the risk for disease progression?” Newly diagnosed patients (N=227) with Stage II/III 
breast cancer were randomized to Assessment only or Intervention plus Assessment arms. 
The model guided the design of a multicomponent biobehavioral intervention [(BBI), i.e., 
understanding and reducing stress, disease/treatment information, problem solving, assertive 
communication, social support, body image/sexuality, and health behaviors]. It was 
delivered in a group format of 18 weekly sessions (intensive phase) followed by 8 monthly 
sessions (maintenance phase). Trial data showed robust, durable gains across secondary 
outcomes (i.e., reduced negative mood and physical symptoms, increased social support and 
health behaviors, more favorable chemotherapy dose intensity) for the Intervention arm in 
contrast to Assessment only; T cell immunity was also enhanced. The maintenance sessions 
were important for retaining (and accelerating) patient gains through 12 months. Study of 
the subgroup of patients with moderate to severe depressive symptoms showed the BBI 
reduced depressive symptoms but also inflammation (Thornton, Andersen, Schuler, & 
Carson, 2009). Notably, after a mean of 11 years, the BBI arm had a reduced risk of breast 
cancer recurrence [Hazard Ratio (HR)=0.55 (95% CI 0.32–.96), p=.034] compared to 
Assessment only patients. Even for those who did recur, BBI arm patients versus 
Assessment only patients had significantly improved psychological, social, and immune 
responses in the 12 months following recurrence diagnosis and a lower risk of breast cancer 
death [HR 0.35 (95% CI 0.17–0.74), p=0.006].
Box B2: BBI generalizability (Brothers, Yang, Strunk, & Andersen, 2011; Thornton et al., 
2014). BBI components have been tailored for high-risk groups. BBI components with 
Cognitive Behavioral Therapy (CBT) treated cancer patients with major depressive disorder 
and led to depression remission. BBI components were combined with Hope Therapy and 
mindfulness to successfully reduce anxiety and improve positive affect and QoL for patients 
with gynecologic or breast cancer with recurrence.
Path T2: STEPS: Conceptualizing EBT dissemination/implementation (DI; Andersen & 
Dorfman, 2016). A determinant framework specified the levels of action and means to 
address the DI gap of EBTs in cancer control. STEPS (Setting, Therapist, Education, 
imPlementation and Sustainability; see Fig. 3) is multidimensional (setting, therapist, 
patient) and multilevel, visually suggesting the increasing effort needed to achieve sustained 
EBT implementation. In health psychology there are dissemination studies (e.g., Jones et al., 
2013), though few data on implementations (Kelly et al., 2000). In cancer control there are 
isolated studies of dissemination (Clark et al., 2012) and none of implementation (Neta et 
al., 2015).
Box C. Test of STEPS and BBI dissemination (Brothers et al., 2015). Guided by STEPS, 
multimodal education was offered from 2011 to 2016 in BBI Institutes to oncology mental 
health providers. For this, BBI was rebranded as Cancer to Health (C2H) 
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[www.cancertohealth.osu.edu] and manuals revised for applicability to newly diagnosed 
male and female patients with any disease site and < 8th grade literacy (reading level). BBI 
was taught by expert trainers using a combination of lectures (40%), role play and group 
discussions (35%), practice experientials (25%), and therapists’ “hands on” familiarity with 
the therapist manual and patient guide book. The trainee group was large (N=128) and 
professionally and geographically diverse, representing 33 states in the US, Puerto Rico, and 
foreign countries (Brazil, Israel, Kenya, and Malaysia), with the majority employed in 
community settings. Evaluations of the training were very positive, and trainees evidenced 
demonstrable improvements in BBI knowledge and also facility with using the treatment 
components clinically in analogue assessments. Training generated positive attitudes toward 
and high self-efficacy to use BBI, with each predicting their intentions to use BBI post 
Institute.
Box D1: Test of STEPS and BBI implementation, sustainment (Ryba, Brothers, & 
Andersen, 2017). Following the Institutes, therapists received six months of support and 
guidance to achieve setting readiness. Support focused on four areas: a) adaptation planning, 
i.e., assisting therapists to determine “fit” of BBI with their patients and setting; b) quality 
monitoring, i.e., monthly (6) conference calls to review BBI principles, problem solve 
implementation challenges, and encouragement to use patient reported outcome measures to 
enable therapists to make data-informed clinical decisions; c) marketing materials, e.g., BBI 
information sheets; and d) financial, i.e., business plan templates to secure resources for 
implementation, if needed. Unlike the majority of implementation efforts, no support was 
provided to the setting/organization; therapists alone were responsible for making BBI 
happen. Over 75% of therapists participated in the support efforts, with their self-efficacy 
and positive attitudes toward EBTs continuing to increase. Therapists’ BBI usage was 
impressive; the proportion of therapists’ patients treated with BBI ranged from 58–68% 
across 2-, 4-, and 6-month follow-ups, with additional data showing sustained usage at 12-
months (71%). As predicted by STEPS, both therapists’ positive attitudes toward BBI and 
setting factors (supervisors’ positive attitudes) were associated with usage.
T3: Understanding implementation at the setting level (Williams, Brothers, Ryba, & 
Andersen, 2015). During conference calls, therapists described challenges to 
implementation. Qualitative data suggested themes subsequently labeled as person (i.e., 
attitudes, statements, and behaviors of key individuals) and environment (e.g., financial 
resources). Both factors influenced how easily implementation barriers could be addressed, 
with person support potentially more important. At the environment/setting level, most 
barriers could be overcome with more resources, but therapists also reported that some 
administrations were unable to prioritize funds for any new EBT offering (not limited to 
BBI), in part due to an economic recession. This information was collected across Institutes 
and incorporated to enhance trainees’ understanding of potential facilitators/barriers and, in 
turn, help in their generation of solutions.
Translational summary—The overarching goal is development and testing of 
psychological treatments for cancer patients, understanding the mechanisms of their efficacy, 
and promoting dissemination and achieving wide implementation. Basic research and theory 
grounded the development and testing of the biobehavioral intervention. Designed for the 
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newly diagnosed, non-metastatic breast cancer patient and offered in a group format, robust 
psychological, behavioral, biologic, and disease endpoint effects came from the efficacy 
trial. Later data showed the clinical effectiveness of BBI components for targeted treatments. 
The DI data demonstrated that therapists could be reliably educated and clinically trained, 
empowered with positive attitudes and high intentions to implement, and subsequently show 
high, sustained, BBI usage.
A Collaborative Study Using a Type 2 Hybrid Design
A multisite translational study was designed to test the “real world” clinical effectiveness of 
BBI on cancer patient outcomes and to determine the fidelity of BBI as implemented by 
newly trained oncology mental health providers from diverse settings. Using a Type 2 
Hybrid design, the test was under conducted “medium” complexity circumstances. That is, it 
was not the “worst” because the therapists had been well trained in the content and processes 
of BBI usage (see C above) and supported in the earliest months of BBI implementation (see 
D1 above). But, it was not the “best” circumstance either, as unlike some implementation 
tests (Greenwald, 2000), the period of implementation support had ended, there was no 
internal or external support for their conduct of a program evaluation, and no added 
advantage in the settings, such as accrual capitation, to enroll patients.
To study the clinical effectiveness of BBI, patient reported fidelity and outcome measures 
previously sensitive to BBI effects were used. These measures, rather than pragmatic ones, 
enabled direct comparison of findings from the efficacy RCT. The Reliable Change Index 
(RCI; Jacobson & Truax, 1991) documents the magnitude and reliability of patient 
improvement. To study implementation, two DI perspectives were considered. The first was 
Landsverk’s (2013) suggestion that fidelity/integrity be built into the research design by 
addressing external validity. Thus, a multisite design provided diversity of therapists, 
patients, and economic models of care and geographic locales of settings. To further blend 
research domains, fidelity as conceived in clinical effectiveness studies was measured: 
treatment adherence/differentiation and therapist competence and relational. Secondly, 
Chambers, Glasgow and Srange (2013) suggest the ultimate benefit of an EBT is its ability 
to “fit” within the setting. Thus, the implementation test used a strategy in which therapists 
could determine BBI delivery format, sessions conducted, components used, etc. rather than 
proscribing such as is usually the case.
METHODS
Participants
Sites—Fifteen facilities in Alabama, California (3), Illinois (2), Indiana, Iowa (2), 
Kentucky, Maine, Massachusetts, Pennsylvania, and Texas (2) participated. The majority 
(73%) were in the community [hospitals (n=7, 47%), Cancer Support Community (n=3, 
20%), oncology practice (n=1, 7%)], while four (27%) were National Cancer Institute-
designated Comprehensive Cancer Centers.
Therapists—Therapists (N=15) were mid age (M=43.4 years, S.D.=10.3, range: 26–62) 
and included males (n=3) and females (n=12). Professionally, there were doctoral-level 
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psychologists (n=7, 47%), master’s-level social workers (n=6, 40%), a psychology 
postdoctoral fellow (n=1, 9%), and a master’s-level mental health professional (n=1, 9%). 
They had received their terminal degree 14.3 years previously (S.D.=9.2, range: 1–29), had 
been licensed for 11.8 years (S.D.=9.0, range: 1–27), and in their current position an average 
of 5.6 years (S.D.=6.6, range: 0.2–24). All were employed full time and, on average, spent 
70% (S.D.=22%, range: 30%–100%) of their hours per week in service provision, 18% 
(S.D.=21%, range: 0%–70%) on administrative tasks or meetings, and 7% (S.D.=10%, 
range: 0%–32%) on teaching/supervision.
Cancer patients—Across the sites, 158 patients (median=10; range 2–25) were accrued. 
Patients were middle aged (M=53.4 years, S.D.=9.9) and primarily Caucasian (85%) and 
female (87%). They had received a minimum of a high school education (98.7%), and many 
were employed (47%) with 52% having an annual household income ≤$75,000, and 87% 
living in an urban area. Only 51% reported being married. Twelve different cancer sites were 
represented, with the most common being breast (54%), gynecologic (19%), and colorectal 
(6%). Extent of disease was local (32%) or regional (46%) rather than distant (13%) or 
recurrent (13%) and the average time since diagnosis was 2.0 years (S.D.=5.7). At baseline, 
71% (112) of patients were in treatment or recovering; 28% were post-surgery, 57% 
receiving chemotherapy, 29% receiving radiation, and 1% received a bone marrow 
transplant. The remaining 29% (46) had completed treatment longer than 6 months 
previously; of these, 20% had received chemotherapy, 20% radiation, and 1% bone marrow 
transplant.
Procedures
Providers learned of the BBI Institutes via national listserves [e.g., APA’s Division 12 
(Clinical Psychology) and Division 38 (Health Psychology), Association of Oncology Social 
Workers], the website (cancertohealth.osu.edu), and word of mouth. During the final 
afternoon of training for Institutes 1–5, providers (N = 128) learned of the ongoing Cancer 
to Health Implementation (C2H-I) study. Described as a program evaluation of BBI, 
therapists learned that a C2H-I Data Coordinating Center (DCC) at The Ohio State 
University would administer the study and provide the following: 1) A study coordinator to 
answer questions and provide guidance for accrual, data collection, and related matters. 2) 
Templates for IRB submission. Settings without a local IRB submitted and had protocols 
reviewed through the DCC’s submission to the Ohio State IRB. 3) BBI marketing materials 
(e.g. patient brochures). 5) Free patient manuals and relaxation CDs for every patient 
accrued. 6) A web based (Qualtrics) site for therapist and patient data collection. 7) Within 
60 days of completion of data collection, provision of a site-specific summary and de-
identified data set.
Therapists were responsible for IRB submission, patient accrual, and providing information 
to patients to enable completion of study measures. Therapists were required to provide data 
on BBI components delivered and homework assigned via Qualtrics. Regarding BBI 
implementation, it was required that BBI be available as part of standard psychosocial 
offerings in the setting. The BBI therapist manuals detailed delivery of 26 sessions (18 
weekly intensive, 8 monthly maintenance) in a closed group format. BBI core content was 
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stress conceptualization, disease information and MD communication, problem solving, 
assertive communication, and social support. Sexuality, body image, and health behavior 
(diet, exercise) were also included. The manual detailed component specific coping 
strategies (e.g., progressive muscle relaxation for stress conceptualization) and homework 
assignments (e.g., practice relaxation 3–4 times, 20 min. each, per week). Therapists were to 
assign, monitor, and engage patients sufficiently to achieve patient usage of the strategies at 
the recommended level. The patient guidebook summarized session content and had work 
sheets to be completed during sessions.
During training, it was noted that BBI delivery to individuals was acceptable and was, in 
fact, recommended as a strategy for therapists to become facile with the content and 
treatment strategies prior to conducting groups. It was made explicit that BBI might require 
adaptation to a setting/patient group, with examples provided, such as omitting or shortening 
content areas, providing fewer sessions, altering the order of sessions. It was, however, 
recommended that any adaptation retain session 1, Stress Conceptualization, and the 
teaching of progressive muscle relaxation, with CD provision and app versions available. 
Inclusion of maintenance sessions was strongly recommended.
IRB documents were uniform in describing procedures of patient accrual and assessment. 
Eligibility criteria were the following: new (initial) diagnosis of invasive cancer, age ≥21, 
and able to give informed consent. Exclusion criteria were the following: estimated survival 
< 2 years; non-ambulatory; concurrent significant sensory deficit or diagnosis of organic 
brain syndrome, dementia, mental retardation, or major mental illness (e.g., schizophrenia); 
and, non-English speaking. Across sites patients seeking psychosocial services were 
assigned to any available therapist. If BBI was an appropriate treatment for an assigned 
patient, the therapist considered the inclusion/exclusion criteria. For those meeting criteria 
and accepting BBI, patients were informed of the program evaluation study. Across sites, 36 
patients approached did not consent to participation. If a group was planned, the non-
consenting individual was included with others who did consent and participate in the 
evaluation. Participating patients completed pre/post psychological measures, either using 
paper/pencil forms (provided by the therapist but mailed to the DCC) or via Qualtrics 




Adherence/differentiation: For each session, therapists reported the following: 1) 
Attendance, 2) Format [group (open, closed), individual], 3) Session duration (in minutes), 
4) Delivery of each treatment component (yes/no), 5) Delivery/review of homework (yes/no) 
by component, and 6) delivery of other interventions.
Competence and relational: Two measures of therapist competence were used (Andersen, 
Shelby, et al., 2007). The Component Usage asks a patient to report usage of 11 strategies 
(e.g., progressive muscle relaxation practice) during the last month on a nine-point 
frequency scale (e.g., 0= not at all, 1=once a month; 2=2–3 times per month; 3=once per 
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week; 4=2–3 times a week, 5=4 per week; 6=5–6 per week; 7=once a day; 8=2 or more 
times a day). The Component Evaluation uses 14-items to assess the helpfulness of BBI 
components/strategies (e.g., “relaxation practice with tapes”), each rated on a 4-point Likert 
scale of helpfulness (1=not at all helpful, 2=a little bit, 3=moderately, 4=very helpful). The 
patient/therapist relationship was assessed (Andersen, Shelby, et al., 2007). Relational/
Cohesion had 2 items for patients to rate a) felt support during treatment and, b) involvement 
in treatment, each on a 10-point scale ranging from 0=not at all supported/involved to 
9=extremely supported/involved.
Clinical effectiveness: Patient reported—Measures sensitive to BBI effects were 
used. They are reliable, valid, and common to cancer intervention studies (e.g., Antoni et al., 
2001).
Individual difference: Cancer stress: Interventions may be differentially effective 
depending on initial distress levels. As previously (Andersen et al., 2004), cancer-specific 
stress was tested as a covariate of treatment outcome with the Impact of Events Scale (IES; 
Horowitz, Wilner, & Alvarez, 1979). Using 15 items, patients rate the frequency of intrusive 
thoughts and avoidant thoughts and behaviors in the previous week on a 5-point Likert scale 
(0=not at all to 4=often). Items are summed for a score ranging from 0 to 75. Cronbach’s 
alpha was 0.86.
Primary: Emotional distress: The Profile of Mood States (POMS; McNair, Lorr, & 
Droppleman, 1971) has 65 items assessing negative mood (e.g., happy, sad) experienced in 
the last week, rated on a 5-point Likert scale (0=not at all to 4=extremely). A Total Mood 
Disturbance Score (TMD) score, ranging from −32 to 200, is calculated by summing the 
tension-anxiety, depression-dejection, anger-hostility, fatigue-inertia, and confusion-
bewilderment subscales and subtracting the vigor-activity subscale. Cronbach’s alpha was 
0.92.
Secondary: BBI component specific measures were used. 1) Social support. The Perceived 
Social Support from Family (Procidano & Heller, 1983) scale has 20 items assessing support 
needs fulfilled by one’s family. Items are summed and scores range from 0 to 20. 
Cronbach’s alpha was 0.70. 2) Sexual functioning. The Sexual Experience Scale (Derogatis 
& Melisaratos, 1979) (one item) assesses global sexual satisfaction on 9-point Likert scale 
(0=could not be worse to 8=could not be better). 3) Physical activity. The Godin-Shepard 
Leisure-Time Physical Activity Questionnaire (PAQ; Godin & Shephard, 1985) is a seven-
day retrospective measure of leisure-time physical activity. Responses are transformed to 
metabolic equivalent task (MET) values, i.e., the rate of energy consumption during a 
specific physical activity. Then, the following health-related categories are used: 2=active 
(≥24 METS), 1=moderately active (14–23 METS), 0=insufficiently active (<14 METS). 4) 
Dietary habits. The Food Habits Questionnaire (Kristal, Bowen, Curry, Shattuck, & Henry, 
1990) has 19 items assessing dietary behaviors, e.g., avoiding fat. Items are scored on a 5-
point Likert scale (0=usually/always to 3= rarely and 4=not applicable) and then averaged to 
provide a total score ranging from 0 to 4, with higher scores indicating greater adherence to 
a diet lower in fat and higher in fruits and fiber.
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The representativeness of the C2H-I settings, therapists, and patients were compared to BBI 
Institute data (N=99 sites, N=128 therapists) for contextual analysis. For the primary 
analyses, data from all sites were merged and checked for anomalies. Descriptive statistics 
are reported for implementation fidelity. When relevant, data are compared with those from 
the BBI efficacy RCT. Clinical effectiveness is tested with pre-treatment (baseline) to post-
treatment change on patient outcome measures using hierarchical multiple linear (HLM) 
regression analyses. Assumptions underlying the analyses were checked. The primary 
outcome was the POMS total mood disturbance, with the Impact of Events scale (IES) tested 
as a moderator. In hierarchical linear model (HLM) regressions, variables were entered in 
the following order: (1) baseline IES score; (2) time; and (3) interaction of IES and time in 
prediction of POMS. The same procedure, excluding the IES, was used for the secondary 
outcomes. Significance was specified at the 0.05 level. All statistical analyses were 
conducted using IBM SPSS 22. Additionally, the Reliable Change Index (RCI; Jacobson & 
Truax, 1991) was used to determine the magnitude and reliability of patient improvement. 
For it, RCI = (x2 − x1)/ 2(SE)
2 , where x1 is a patient’s pre-treatment score, x2 is the post-
treatment score, and SE represents the standard error of measurement of the measure. A 
significant change is indicated by an improvement of RCI*1.96 on the measure. Finally, for 




Setting level—Trainees from five BBI Institutes (N=128) came from 99 different settings. 
Of them, therapists from 38 sites (38%) expressed interest in participating in C2H-I and 16 
(16%) joined. IRB applications were completed an average of 13 months (S.D.=9.1) post-
Institute; the Data Coordinating Center (DCC) was the IRB of record for 5 sites. Accrual 
began approximately 3 months (S.D.=2.8) later, roughly 1.5 years after completion of 
training. Of the 16 sites, 15 sites accrued patients and collected data as of March 2017.
Therapist level—Of the 128 BBI trainees, 15 became investigators; 5 of the 15 also had 
BBI trained co-therapists. The 15 represent 12% of the eligible sample. The 15 therapists 
and 5 co-therapists represented 38% of the full-time oncology therapists (52) employed at 
these sites. Compared to the trainee group, the C2H-I therapists did not differ in age, years 
since terminal degree, licensure, duration of current position, discipline, or time spent in 
clinical work or teaching (all p’s > 0.25). The only significant difference was weekly time 
spent on administrative tasks (t=−2.45, df=127, p < 0.02), with C2H-I therapists reporting a 
greater percentage of time per week, 18% (S.D.=21%) versus 9% (S.D.=13%).
Patient level—Across sites, 158 patients were enrolled (M=10.53). N’s by site were as 
follows: Alabama=15; California A=23; California B=11; California C=8; Illinois A=13; 
Illinois B=10; Indiana=9; Iowa A=12; Iowa B=11; Kentucky=6; Maine=3; Massachusetts=7; 
Pennsylvania=3; Texas A=25; Texas B=2). Of the 158, 1 patient was later found ineligible 
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and 24 left treatment, resulting in 133 (84%) patients completing pre- and post-intervention 
assessments.
When applying to the BBI Institutes, therapists reported the general characteristics of 
patients typically treated (Brothers et al., 2015). Comparison of the C2H-I therapists’ 
application data with the C2H-I patients showed no differences in ethnicity or income. 
However, C2H-I patients were more likely to be female (t=2.27, df=157, p=0.03), Caucasian 
(t=2.02, df=157, p=0.05), live in an urban area (t=−10.21, df=155, p < 0.01), and have a 
breast cancer diagnosis (t=8.69, df=157, p < 0.01) than the “average” patient treated by all 
institute therapists.
Implementation: Fidelity
Format—In the efficacy RCT BBI was delivered in closed groups, i.e., patient entry at 
session 1 and exit at the end of Maintenance (session 26). In C2H-I, eight sites (53%) 
conducted closed groups, 5 sites (33%) conducted ‘managed’ open groups, one site (7%) 
conducted both open and closed groups, and one site conducted individual treatment only 
(7%). Patients in managed open groups completed 26 sessions as follows: 1) Session 1 was 
conducted individually. 2) A patient then joined a group as a module was begun (see Table 1 
for designation of modules a–d). 3) When a patient completed a–c (regardless of the order), 
s/he would begin Maintenance (d). At the patient level, 15% received individual treatment, 
50% received treatment in “managed” open groups, and 35% received treatment in closed 
groups.
Duration—For the efficacy RCT, BBI was delivered in 18 weekly sessions (intensive) and 
8 monthly sessions (maintenance), with each being 90 minutes. As expected, C2H-I 
individual sessions were <60 minutes whereas group sessions were > 60 minutes. The total 
number of sessions delivered across sites was 597 (Md=35, range 2–196; see Table 1). Per 
site intensive sessions ranged from 3 to 14, with a mean of 10.6 (S.D.=2.91; Md=11.1). The 
duration of individual sessions (196 delivered) averaged 39 minutes (S.D.=14, Md=40, range 
10–60), open group sessions (279 delivered) averaged 86 minutes (S.D.=12, Md=90, range 
19–105), and closed group sessions (122 delivered) averaged 92 minutes (S.D.=14, Md=90, 
range 15–120). Ten sites (67%) included maintenance, with a mean of 2.8 sessions 
(S.D.=1.78) and a median of 2.75. In comparison to the BBI RCT, C2H-I BBI was 
implemented with 59% and 23% of the number of intensive and maintenance sessions, 
respectively.
Content delivery—For the BBI RCT, BBI Session 1 provided a conceptualization for the 
stresses of cancer and introduced progressive muscle relaxation, and it was recommended 
that C2H-I implementations begin with this key session. The remaining core components are 
information and communication, problem solving, assertive communication, and social 
support. In C2H-I, core topics were delivered to roughly 60–70% of the patients treated with 
BBI (see Table 1). Fewer patients, 50–56%, were provided coverage of sexuality and health 
behaviors.
For the BBI RCT, patients were assigned homework at the end of sessions and it was 
reviewed at the beginning of the following session. In C2H-I, therapists reported delivering 
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homework in the majority of sessions (67%), an average of 6.24 sessions (S.D.=2.73, range: 
0.00–10.00) of the 10.69 conducted. Eighty nine percent (89%) of patients had at least 1 
session in which homework was reviewed. Homework was most frequently included in the 
core component sessions.
Therapist competence and relational—Therapists were responsible for directing 
patients to use the BBI coping strategies and communicating a level of compliance (see 
“Component usage – BBI Recommended” column in Table 2). Excepting social support (3.5 
vs. 4), patients’ reported usage of core strategies exceeded the rate recommended (see Table 
2, “Component usage – Reported”). Levels lower than recommended were reported for non-
core components: sexuality (M=1.91 vs. 3), indicating that patients used sexuality strategies 
(2–3 times per month versus the recommended once per week) and dietary strategies to 
reduce fat (M=5.66 vs. 7) and increase fiber (M=5.93 vs. 7).
Regarding component helpfulness evaluation (rated 0–4; see Table 2), patients found BBI to 
be very helpful, with a grand mean across components of M=3.48 (S.D.=0.71). Components 
with the highest helpfulness ratings were social support (M=3.70, S.D.=0.60), stress 
conceptualization (M=3.65, S.D.=0.58), and assertive communication (M=3.61, S.D.=0.61). 
Even sexuality, with the lowest rating (M=3.03, S.D.=0.85), was still regarded as moderately 
helpful. Regarding the therapeutic relationship, patients reported high levels of perceived 
support (M=7.97, S.D.=1.47) and high involvement in BBI treatment (M=7.52, S.D.=1.60).
Clinical Effectiveness
Time between pre- and post-intervention assessments averaged 17 weeks (S.D.=5.5 weeks). 
The moderator test revealed baseline IES to independently predict pre-to-post change in the 
POMS above and beyond the effect of time (β=0.56, p < 0.01), but the interaction of IES and 
time was not significant (ΔR2 < 0.001, β=0.01, p=0.96). The latter indicates that regardless 
of initial IES magnitude, patients improved. Previously greater POMS improvements were 
found for those with initially higher IES scores (Andersen, Farrar, et al., 2007); here, BBI 
was effective across patients. As predicted, patients reported significant pre- (M=39.7) to 
post-intervention (M=22.7) decreases on the POMS (R2=0.06, β= −0.24, p < 0.01). Also, the 
Reliable Change Index indicated POMS improvement was reliable and significant for 26% 
of the patients.
For secondary outcomes, there was a significant pre- (M=1.39) to post-intervention 
(M=1.52) increase in PAQ physical activity scores (R2=0.02, β=0.13, p < 0.05) with patients 
reporting being “moderately active” at pre-and “active” at post. No significant pre/post 
changes (ps ≥ 0.06) were found for the remaining secondary measures.
As in the BBI RCT, moderation analyses tested the relationship between component-specific 
outcomes and strategy usage. Change in POMS was tested with stress conceptualization use 
and progressive muscle relaxation use, and change in the PAQ was tested with physical 
activity strategy use. The moderation effects were not significant (ps ≥ 0.05).
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Relationship of Clinical Effectiveness and Fidelity
Correlational analyses related POMS change to all fidelity variables and of them, treatment 
format covaried. POMS scores were correlated with BBI format (r=0.25, p < 0.05), such that 
patients in groups reported larger POMS decreases than patients treated individually, −16.1 
versus −0.1, respectively. Further, POMS scores were correlated with group type (r=0.22, p 
< 0.05), such that participants from open groups evidenced larger decreases than patients in 
other treatment formats, −18.8 versus −7.7, respectively. Similar analyses examined fidelity 
and physical activity (PAQ) scores, finding that PAQ scores were also correlated with BBI 
format (r=0.24, p < 0.05), such that patients in groups reported PAQ increases (M=0.15) 
while patients treated individually reported PAQ decreases (M=−0.21). PAQ scores were 
also correlated with session length (r=0.30, p < 0.01), such that patients whose BBI sessions 
lasted longer (i.e., in group treatments) reported greater improvements in PAQ physical 
activity scores.
DISCUSSION
The overarching goal to add substantively to both the implementation and clinical 
effectiveness literatures was achieved. While there are examples of treatment 
implementations “going to scale” (Kilbourne et al., 2012; Solberg et al., 2015), to our 
knowledge, this is the first use of a hybrid design in the health psychology DI literature and 
more generally, it is one of the few studies of adaptation in the context of implementation 
(Chambers, 2018). A type 2 hybrid design studied co primary aims to determine 1) the 
feasibility and utility of a flexible EBT implementation strategy, and 2) the clinical 
effectiveness of an EBT as implemented by newly trained providers. In this study, adaptation 
was anticipated and planned but not regimented (Bell, Marcus, & Goodlad, 2013). Data 
detailed the adaptations and showed the BBI to be implemented with fidelity. Sixty to 
seventy percent of the core content was provided and homework included, with minimal 
additions of other content or strategies by the therapists. Moreover, data suggest the 
therapists were competent, with their reports of treatment delivery consistent with patient 
reports of treatment receipt/usage, which was high. Patients’ satisfaction with BBI was high 
and they viewed their therapists as competent and supportive. Finally, effectiveness data 
show significant reductions in patients’ negative moods and for 26% of the sample, the 
magnitude being significant and reliable.
Conditions under which the type 2 design is best used have been described (Curran et al., 
2012). One is having a strong base of indirect evidence for the clinical intervention to be 
tested. For BBI, efficacy tests showed it to yield robust positive effects which were 
conceptually replicated with studies of tailored versions. All of the latter, however, came 
from the same research group with no effectiveness tests by others. Overall, we were aware 
of the high uptake of BBI (Ryba, et al., 2017), but neither the fidelity of therapists’ 
implementations nor impact of BBI on patient outcomes was known. Another condition of 
the type 2 design is conduct when there is “implementation momentum.” Specifically, C2H-I 
therapists began accrual ten months after their training, consultation for BBI adaptation and 
addressing barriers, and implementation support (Williams et al., 2015). More broadly, new 
standards and cancer patient guidelines specified the use of EBTs (e.g., “cognitive change, 
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biobehavioral strategies… treatments using stress reduction, problem solving, assertive 
communication”) (Andersen et al., 2014, p. 1610, 1615). Thus, conditions for a Type II 
study were timely.
The breadth of the fidelity data clarifies the nature of BBI provided, and they show an 
adapted BBI (i.e., planned or purposeful changes to the design or delivery of the intervention 
to retain fidelity to fundamental elements) rather than a modified one (i.e., planned or 
unplanned changes to improve treatment fit, engagement, or effectiveness) (Wiltsey Stirman, 
Gutner, Crits-Cristoph, Edmonds, Evans, & Beidas, 2015). We use Wiltsey Stirman et al.’s 
(2017) definition of types of content level modifications. Considering them, the data suggest 
there was little tailoring (minor alterations), addition or diffusion of non BBI treatments or 
components, no shortening of session time, no lengthening of number of sessions or time, or 
no repeating of content not proscribed for such. Instead, what occurred was removal or 
shortening coverage of non-core components (e.g. health behaviors, maintenance). A novel 
“real time” adaptation by some therapists occurred, a reordering of BBI components after 
the foundational session. These data shed light on how the BBI was adapted into routine 
care, aligning with the growing interest to precisely capture the nature of adaptations of 
implemented EBTs (Chambers & Norton, 2016).
NIH recommendations to achieve treatment fidelity in implementations (Bellg et al., 2004) 
were incorporated into the design and conduct of BBI dissemination, support to providers 
for implementation, and the type 2 study. This included several elements: a) rigorous BBI 
training, also resulting in therapists having high motivation and intent to implement BBI; b) 
feedback to therapists on their anticipated adaptations, making clear that drift to non BBI 
content or strategies would change an empirically supported treatment to one without 
support; c) problem solving implementation barriers; d) providing manuals and supporting 
materials for therapists and patients; and, e) implementation support.
A multicomponent assessment of fidelity was used (Schoenwald, et al., 2011), but there is 
currently no standard metric as to what constitutes implementation with fidelity versus not. 
Regarding differentiation, the low frequency of “other treatments offered” entries suggested 
addition of non-BBI content was negligible. Regarding adherence, the modular/component 
structure of BBI facilitated the fidelity analysis. Importantly, the evidence suggests that the 
fidelity of BBI implementation was at the least acceptable in overall level, and when 
compared to BBI RCT data, implemented met or exceeded several benchmarks. Regarding 
adherence, the core components (specific factors) of BBI had the highest levels of delivery, 
ranging from 60 to 100% of patients receiving the content. For the non-core content 
adherence was lower, in the range of 50–56, perhaps driven by specific circumstances. For 
sexuality/body image, therapists were trained, but for the majority this was unfamiliar 
content and one that requires considerable practice to achieve facility and comfort with 
delivery. For health behaviors, it was suggested that dietary and/or exercise personnel could 
be integrated into the sessions as was done in the RCT. Some delivered the content and 
others used resource persons and or made referrals. An important element of BBI is in- and 
out of session activities/homework, but latter are often removed in routine care (Cook, 
Dinnen, Thompson, Siminola & Schnurr, 2014). Yet, therapists reported delivering 
homework and reviewing homework in the large majority of sessions. Maintenance is a 
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novel aspect of BBI and was important to sustaining change; its inclusion was strongly 
recommended to therapists. While two thirds of the sites offered maintenance, the median 
number of sessions was one third of the recommended dose. Admittedly, BBI is a lengthy 
treatment, comparable to some offerings, such as CBT, though not others. Anecdotally 
suggested, historical circumstances may have also been relevant to the discrepancy between 
the number of sessions offered (11 intensive) versus sessions manualized (18). Much of the 
data collection occurred during an economic recession when personnel budgets for 
psychosocial services became even tighter with some organizations not replacing therapists 
or pressuring remaining ones to limit session numbers to see more patients.
The therapist fidelity data are very positive and reflect the competence of the therapists and 
patients’ satisfaction with BBI. Importantly, therapists’ reports of component delivery (Table 
1) and patients’ reported usage (Table 2) are consistent. Moreover, patients’ reported usage 
of core strategies typically exceeded the rate recommended for the RTC. Patients viewed the 
therapists as very supportive and BBI as a very helpful treatment, with the rating virtually 
identical with those from the RCT (Andersen, Shelby, et al., 2007). Collectively, the fidelity 
data show BBI is “implementable,” but contextually, it is a treatment showing high 
acceptability, engagement, and satisfaction by therapists and patients. Metrics such as these 
provide the rationale and data for managers to advocate for service expansion and for 
settings to expand market share.
The analyses show significant change on the POMS, with large magnitude, reliable mood 
improvement for 26%. Physical activity changed significantly with time as it did in the BBI 
RCT. Regarding the latter, 71% of the patients were still receiving cancer treatment at 
baseline, and maintaining, resuming or beginning physical activity anew during this period 
is difficult. We do not know, but the gains might have been greater if more maintenance 
sessions had been included as the RCT showed acceleration of gains during maintenance 
(Andersen, Shelby, et al., 2007). With the dual aims, we were able to examine the 
relationship of fidelity and patient outcome data. Multiple aspects of BBI dose [e.g., number 
of sessions (−.033), minutes attended (−.137), receipt of components (<.001 to .135)] and 
POMS change showed no relationship, whereas BBI offered in groups was associated with 
greater gains. In general, research suggests that when compared to the original, adapted 
protocols show small, if any, differences in effects (e.g., Stirman et al., 2017). We do know, 
however, if the passage of time accounted any patient improvements.
The study’s strengths and weakness are considered. The multiple-dimension heterogeneity 
of the locales, models of care provision, therapists, and patients are key to the 
generalizability and implications of the findings. Comparison amongst the latter was not 
intended nor was it possible because of the variable rates of accrual. Unlike the RCT, 
therapists came from multiple disciplines, heterogeneous experience levels, included males, 
and a range of care circumstances. The therapists spent more time per week on 
administrative tasks than the other Institute attendees, perhaps providing the time to manage 
study tasks. Unlike the RCT, the patient sample included males, many disease sites, and was 
geographically diverse. However, these individuals received treatment, which few cancer 
patients do (Owen, Goldstein, Lee, Breen, & Rowland, 2007). While cancer patients with 
less economic, educational, and other resources were present, they were under represented.
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Type 2 hybrid designs test clinical and implementation aims, but a “test” need not be a RCT, 
and here, two conditions supported the use of a non-randomized Type 2 design. For one, 
prior efficacy studies showed robust gains with BBI and prior data showed BBI delivery to 
the majority (60–70%) of providers’ patients, suggesting they would be reluctant to offer a 
treatment other than BBI. Secondly, the implementation strategy—flexible rather than 
proscribed BBI delivery—was neither complex nor taxing for therapists or settings and was, 
in fact, an advantageous one to study. Regarding the dual aims, trials can be described in 
terms of their original intent using the PRECIS-2 metric (PRagmatic Explanatory 
Continuum Indicator Summary; Loudon et al., 2015). By design, this study was pragmatic in 
terms of eligibility, recruitment, setting, primary outcome, and primary analysis, but 
reflected a stronger efficacy orientation in its organization, flexibility in EBT adherence and 
delivery, and follow-up [See Supplementary Materials]. Regarding clinical effectiveness 
measures, those from BBI trials were used for explicit comparison. In studies with other 
purposes, pragmatic measures, such as those recommended in guidelines for the assessment 
of anxiety and depressive symptoms in cancer patients or those included in the Patient-
Reported Outcomes Measurement Information System (PROMIS; see http://
www.healthmeasures.net/explore-measurement-systems/promis) can be chosen. The fidelity 
measures reflected current conceptualizations (e.g. Schoenwald et al, 2011). Obtaining 
additional specifics of the component delivery (e.g., “Was social support from employers, 
friends, family, partner, and children discussed, as is manualized?”) added burden. However, 
detail on the nature of EBT adaptations is increasingly important in implementation science 
(Chambers & Norton, 2016).
In conclusion, models describe stages of intervention development, dissemination, and 
implementation. The BBI provides one example, moving from theory, RCT and companion 
studies, inclusion in treatment guidelines, dissemination, implementation, to this study of 
implementation fidelity and patient outcomes. C2H-I was a partnership with front line 
providers, which is sorely needed (Cook, 2018), and as such the data sheds light on the 
implementation adaptations that occur in routine care. These data show that a strategy of 
therapist/setting-directed implementation can still achieve treatment fidelity, and further, 
clinically important outcomes for patients in the community. The simultaneous study of the 
two challenges of disseminating and implementing mental health treatments—training and 
supporting providers and achieving fidelity and documenting patient outcomes—might lead 
to the greatest scientific gains in implementation science and clinical effectiveness 
knowledge, with this study providing one example toward the ultimate goal of impacting the 
health and well-being of cancer patients at the population level.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Translational science discoveries (A–E) and theoretical linkages (T1–T5) leading to 
improved population health. Discoveries impact (and interact with) other discoveries (e.g., 
D1 leading to B1) in addition to those specified.
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Biobehavioral Model of cancer stress and disease course with inclusion of depression and 
inflammation pathways.
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Multidimensional framework of Setting, Therapist, Education, ImPlementation and 
Sustainability (STEPS) factors and illustration of increasing activity and engagement 
required of therapists and settings to achieved sustained provision of evidence based mental 
health treatment to patients.
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